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Abstract
Clinical glycomics comprises a spectrum of different analytical methodologies to analyze glycan structures, which provides
insights into the mechanisms of glycosylation. Within clinical diagnostics, glycomics serves as a functional readout of genetic
variants, and can form a basis for therapy development, as was described for PGM1-CDG. Integration of glycomics with
genomics has resulted in the elucidation of previously unknown disorders of glycosylation, namely CCDC115-CDG,
TMEM199-CDG, ATP6AP1-CDG, MAN1B1-CDG, and PGM1-CDG. This review provides an introduction into protein gly-
cosylation and presents the different glycomics methodologies ranging from gel electrophoresis to mass spectrometry (MS) and
from free glycans to intact glycoproteins. The role of glycomics in the diagnosis of congenital disorders of glycosylation (CDG)
is presented, including a diagnostic flow chart and an overview of glycomics data of known CDG subtypes. The review ends with
some future perspectives, showing upcoming technologies as system wide mapping of the N- and O-glycoproteome, intact
glycoprotein profiling and analysis of sugar metabolism. These new advances will provide additional insights and opportunities
to develop personalized therapy. This is especially true for inborn errors of metabolism, which are amenable to causal therapy,
because interventions through supplementation therapy can directly target the pathogenesis at the molecular level.
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Introduction
Technological advances in science are creating a revolution in
the world of clinical diagnostics for rare metabolic disorders.
In many cases, establishing a diagnosis via the traditional care
route is a complex, lengthy process involving multiple con-
sultations by various clinical specialists. The fact that an omics
technique greatly reduces this turnaround time and increases
the diagnostic yield has recently been shown for a cohort of
150 patients presenting with complex neurological disorders
of suspected genetic origin. They compared the number of
solved cases applying either whole exome sequencing
(WES) alone (29.3%) or the standard care pathway (7.3%).
This improvement in diagnostic yield is significant, without
increasing costs compared to the standard diagnostic trajecto-
ry (Vissers et al 2017). However, the percentage of solved
cases of about 30% is still quite low, which is likely caused
by either the lack of sequence coverage of the variant, by
disease causes outside the coding sequences, or the presence
of too many Bvariants of unknown significance^. In this light,
the important connection of genomics with functional -omics
methodologies in the diagnosis of metabolic disorders is rec-
ognized more and more. For example, a combination of WES
and deep clinical phenotyping was applied to 41 patients with
intellectual developmental disorder and unexplained metabol-
ic abnormalities, which resulted in a diagnosis for 28 patients
(68%), and a test for targeted intervention on 18 patients
(44%) (Van Karnebeek et al 2016). For congenital disorders
of glycosylation (CDG), many cases were unsolved until the
inclusion of glycomics into clinical practice, to present the
functional defect (Jansen et al 2016a; Jansen et al 2016b;
Jansen et al 2016c; Van Damme et al 2016; Van
Scherpenzeel et al 2014; Tegtmeyer et al 2014; Carss et al
2013; Iqbal et al 2013). The most important advantage of
integrating functional omics with genomics in the field of
inherited metabolic disorders is the opportunities for therapy,
which do arise from insights into functional, biochemical
pathways. Initial evidence was published for PGM1-CDG
(Tegtmeyer et al 2014; Wong et al 2017). This review dis-
cusses glycomics, its role in CDG diagnostics, presents differ-
ent methodologies, and ends with future perspectives, in
which the horizon of the diagnostic laboratory needs to be
broadened to functionally understand new genetic defects.
Introduction in glycosylation
Protein glycosylation is considered to be the most common
post-translational modification and is ubiquitously present
(Moremen et al 2012). Glycosylation is a non-template driven
process involving multiple competing enzymes (e.g., glycosi-
dases and glycosyltransferases) in the endoplasmic reticulum
(ER) and the Golgi apparatus (GA) as glycoproteins traffic
and mature through the secretory pathway. Therefore, glycan
structures are highly diverse, with multiple possibilities for
branching and linkage (micro-heterogeneity) and differences
in site occupancy (macro-heterogeneity). Glycans are known
to have many important biological functions, such as cell-cell,
macromolecular (e.g., antibody) and pathogen interactions,
protein secretion, protein signaling, and protein folding
(Moremen et al 2012; Defaus et al 2014).
Glycosylation changes have been identified in various dis-
eases, ranging from monogenetic inherited disorders such as
CDG (Jaeken 2011) to multiple types of malignancies; e.g.,
ovarian (Leiserowitz et al 2007), colon (Sethi et al 2014) and
breast cancer (Lee et al 2014), but also observed in other
pathological situations, such as cirrhosis, hepatitis, and neuro-
degenerative diseases such as Alzheimer’s (Palmigiano et al
2016) and Parkinson disease (Russell et al 2017). Therefore,
the analysis of glycosylation in complex biological matrices,
which is called glycomics, has become one of the popular -
omics after the era of genomics and proteomics, especially for
biomarker discovery, treatment monitoring, and also to under-
stand disease mechanisms. This has become more relevant
and promising since the majority of tumor biomarkers en-
dorsed by the Food and Drug Administration (FDA) are gly-
coproteins (Fuzery et al 2013). Most of the markers are only
judged based on their expression level. However, for two gly-
coproteins, glycosylation is included as a biomarker in routine
clinical diagnostics, namely carbohydrate-deficient transferrin
for the detection of CDG and alcohol abuse, and fucosylated
serum alpha-fetoprotein (AFP-L3) for the early diagnosis of
hepatocellular carcinoma (Li et al 2001; Leerapun et al 2007).
It was shown that by including glycosylation in the analysis,
specificity and sensitivity were increased over the native al-
pha-fetoprotein, and intact transferrin mass spectrometry re-
sulted in the direct diagnosis of several CDG-II subtypes (van
Scherpenzeel et al 2015).
There are three types of protein glycosylation in mamma-
lian cells, namely N-, O-, and C-linked glycosylation each
having their own subclasses (Moremen et al 2012). The first
two are the most common types of protein glycosylation in
human cells (Wang et al 2014), and are therefore also the most
studied and best characterized types. This review on clinical
glycomics will be restricted to these two most common types.
N-linked glycans are attached to the polypeptide via amide
linkages to asparagine (Asn) side chains, while O-glycans
are attached through glycosidic linkages to side chains of
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serine (Ser) or threonine (Thr). N-glycans consist of several
monosaccharides, such as N-acetylglucosamine (GlcNAc),
mannose (Man), fucose (Fuc), galactose (Gal), glucose
(Glc), and sialic acid (Sia), which are built in a specific order
(Cummings 2009). Briefly, N-glycans are assembled in the
ER before being further processed and modified in the GA
producing three types of N-glycans, namely complex, hybrid,
and high mannose (Fig. 1a).
In contrast to N-glycosylation, O-glycosylation is assem-
bled directly onto serine or threonine residues without pre-
assembly. Mucin type O-glycans are the most well-known
type of O-glycans with N-acetylgalactosamine (GalNAc) at
the reducing end. Another large group of O-glycans are the
glycosaminoglycans (GAGs) on proteoglycans. GAGs are
long, unbranched carbohydrates containing repeated
GalNAc or GlcNAc residues combined with glucuronic acid
(GlcA) or Gal residues. The other five types of O-
glycosylation are O-linked GlcNAc, -Gal, −Man, −Glc, and
-Fuc. In all of these classes, one or more genetic deficiencies
have been identified (Wopereis et al 2006, Hennet 2012,
Freeze et al 2014).
Clinical glycomics methodologies
For protein N-glycan analysis, the sample preparation usu-
ally starts with the addition of the enzyme N-glycosidase F
(PNGaseF), to cleave the N-glycans from the proteins. The
Fig. 1 Schematic representation of the process of protein N-
glycosylation, the different types of N-glycans (a) and their analysis by
mass spectrometry in CDG (b) (a) The process of N-glycosylation is
started when a glycan precursor is assembled by sequential addition of
monosaccharides onto the lipid anchor dolichol in the membrane of the
ER. The glycan precursor containing 14 monosaccharides (Glc3-Man9-
GlcNAc2) is then transferred en bloc to a specific asparagine residue (N)
within the consensus sequence N-X-S/T (X = any amino acid except
proline, S = serine, T = threonine) in the nascent peptide chain of a protein
(e.g., transferrin) being synthesized by a ribosome. After several glucose
trimming by ER glucosidases, the glycoprotein is transported to the GA,
where the glycans are modified in multiple steps through the action of
various glycosidases (trimming) and glycosyltransferases (prolonging).
All N-glycans share the common core structure of Man3-GlcNAc2, and
are classified into high mannose glycan (onlyMan residue attached to the
core), complex glycan (only GlcNAc residues are attached to the core)
and hybrid glycan (combination of Man and GlcNAc residues are
attached to the core). (b) The two most common plasma glycomics
approaches for CDG characterization are free N-glycans profiling
(glycans released from whole or specific glycoproteins by PNGAseF
digestion; e.g., total plasma glycoprofiling) and intact protein
glycoprofiling (immunopurification protocol without PNGAseF
digestion)
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method is applicable to purified proteins, as well as on
complex biological samples, such as blood, urine, and
CSF. In addition to the analysis of protein-released N-gly-
cans, advances in technology allow the analysis of intact
glycoproteins, which is fast, robust, does not require enzy-
matic digestion, and enables high-throughput analysis
(Fig. 1b).
Traditionally, derivatization is the common step after re-
leasing N-glycans from proteins, because this type of modifi-
cation increases the sensitivity of glycan detection as native N-
glycans have no significant ultraviolet (UV) absorbance. One
could make use of the single reactive carbonyl group at the
reducing end of the glycan and perform reductive amination
with UVor fluorescent tags, such as 2-aminobenzoic acid (2-
AA), 2-aminobenzamide (2-AB), and 2-aminopyridine (2-
AP) (Ruhaak et al 2010; Pabst et al 2009), or permethylate
glycans (Ciucanu and Kerek 1984; Kang et al 2008), thereby
replacing all the hydroxyl groups with methyl ethers.
Recently, a method for sialic acid esterification was reported,
which not only enhances the stability of acidic glycans during
analysis, but also distinguishes alpha2,3 and alpha2,6 sialic
acid linkage (Wheeler et al 2009; Reiding et al 2014).
Disadvantages of derivatization steps are that they could be
incomplete, which creates a biased analysis, as well as the
need for additional purification procedures which can cause
sample loss (Pabst and Altmann 2011).
Several electrophoretic and chromatographic techniques
have been established to separate complex N-glycanmixtures,
such as capillary electrophoresis, ion exchange chromatogra-
phy, hydrophilic interaction liquid chromatography (HILIC),
liquid chromatography (LC), and porous graphitized carbon
(PGC) (Melmer et al 2011). Recently, PGC-LC-MS has
emerged as a popular platform to efficiently separate native
glycans without derivatization steps which greatly reduced
turnaround time of glycomics sample preparation and enabled
the separation of isomeric N-glycans (alpha and beta
anomers). Native N-glycan analysis using the PGC-LC ap-
proach has been successfully applied for glycan biomarker
discovery in ovarian cancer (Hua et al 2013), colorectal cancer
(Sethi et al 2015), and lung cancer (Ruhaak et al 2016).
Electrospray ionization (ESI) and matrix assisted laser
desorption ionization (MALDI) are the two most common
ionization techniques for MS glycan analysis. Both ioni-
zation techniques are very sensitive to analyze proteins,
peptides, glycans, and lipids as low as picomolar concen-
trations. ESI is considered as a soft ionization technique,
and is able to create multiple charged ions for biomole-
cules, such as proteins and peptides, which enables these
large molecules to be analyzed within the mass over
charge ratio (m/z) ranges of the instrument. When coupled
to LC and including standards for calibration, ESI is more
reliable for quantitative analysis than MALDI (El-Aneed
et al 2009; Sturiale et al 2011).
In comparison to ESI, MALDI has the advantages of
being robust, fast, and easy to operate. Additionally,
MALDI allows analyzing the acidic N-glycans in relative
quantities compared to the neutral glycans when derivati-
zation steps, such as permethylation and ethyl esterifica-
tion, were performed prior to MS to neutralize and stabi-
lize sialic acids. Fourier transform (FT-) and time of flight
(TOF)-MS are currently the detectors with the highest
resolution (Wuhrer et al 2004; Pabst and Altmann 2008).
The second might be preferable considering its capability
to analyze large molecules like intact proteins, and the
high maintenance costs of FT detectors.
Unfortunately, there is no general O-glycosidase avail-
able for enzymatic release of all species of O-glycans. For
O-glycan profiling, chemical release by hydrazinolysis or
(reductive) beta-elimination needs to be performed, which
are harsh methods that always yield some side products.
The reductive beta-elimination is the most clean and there-
fore the most commonly used method, since the simulta-
neous reduction of the terminal sugar prevents the peeling
of the glycan due to the alkaline conditions (degradation
from its reducing end) (Thaysen-Andersen and Packer
2014). There are few methods published to simultaneously
profile plasma N- and O-linked glycosylation of CDG pa-
tients (Faid et al 2007; Xia et al 2013). Because of their
limited applicability so far, congenital disorders in the bio-
synthesis of O-glycans have been identified by genetic ap-
proaches. However, for the mucin type O-glycans, intact
apolipoprotein C-III (Apo C-III) profiling is available in a
diagnostic setting (Wopereis et al 2003). One way to cir-
cumvent the need to use harsh conditions to cleave O-
glycans is to analyze native glycopeptides, with the addi-
tional advantage of keeping the information on the attach-
ment site intact (Hoffmann et al 2016). System-wide map-
ping of the N- and O-glycoproteome is envisioned in a
good review of Thaysen-Andersen and Packer in 2014
(Thaysen-Andersen and Packer 2014). This new frontier
in proteomics has the merits of high-resolution MS, com-
plementary fragmentation techniques, and bioinformatic
tools.
Application of clinical glycomics for CDG
diagnostics
CDG are a group of genetic defects with abnormal glycosyl-
ation of proteins, lipids or both. According to the current
guidelines (Jaeken et al 2009), CDG is classified into: protein
N-glycosylation defects, protein O-glycosylation defects,
glycosphingolipid and glycosylphosphatidylinositol anchor
glycosylation defects, and multiple glycosylation pathway de-
fects. Currently, 105 distinct types of CDG have been
reported (Jaeken and Peanne 2017; Peanne et al 2017).
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However, with the emergence of next generation geno-
mics technologies, there were also genes identified that
do not directly involve the glycosylation biosynthesis
pathway, for example defects in nucleotide sugar trans-
port, defects of vesicular transport, defects in O-
mannosylation, O-GlcNAcylation or defects in dolichol
biosynthesis, which lead to abnormal protein glycosyla-
tion (Hennet 2012). CDG are commonly classified by the
localization of the genetic defect (Jaeken et al 2009), in
which CDG type 1 (CDG-I) refers to deficient synthesis
of the precursor glycan in the ER, also including defects
in the cytosol (e.g., PMM2- and PMI-CDG) and the
transfer of the LLO to the protein, including various
OST defects (e.g., DDOST, SST3A, and SST3B). CDG
type 2 (CDG-2) occurs in the GA resulting in modified
glycans on the glycoprotein (Lefeber et al 2011). Since
the majority of these glycosylation disorders showed a
defect in the biosynthetic pathway of protein N-
glycosylation (Freeze et al 2014), the analysis of plasma
N-glycans using MS plays a significant role in CDG
research and diagnostics. The two most common clinical
glycomics approaches for CDG characterization are glob-
al (N-glycans released from whole serum or plasma
glycoproteins, further abbreviated as plasma glycomics)
and protein-specific (e.g., intact transferrin MS & Apo
C-III MS) glycoprofiling (Fig. 1).
The first application of glycomics was ESI-MS for
CDG-I characterization. Transferrin profiles using ESI-
MS on PMM2-CDG patients clearly showed two abnor-
mal peaks corresponding to lack of one and both com-
plete glycans (Wada et al 1992a; Wada et al 1992b).
ESI-MS of transferrin became more ‘mature’ in 2001,
when coupled to LC-MS to create a fast and high-
throughput screening test for CDG (Lacey et al 2001).
A decade later, the emergence of advanced quadrupole
time-of-flight (QTOF) detection in combination with
nanoLC-ESI-MS enabled the development of high reso-
lution intact transferrin glycoprofiling which in turn im-
proved the CDG diagnostics (van Scherpenzeel et al
2015). Normal transferrin IEF profiles have been ob-
served in some CDG-I and -II cases, such as ALG14-
CDG, ALG11-CDG, MOGS-CDG, SLC35A3-CDG, and
SLC35C1-CDG (Lefeber 2016; Al Teneiji et al 2017), as
well as in some defects in sugar metabolism like GNE-
CDG (Voermans et al 2010), NANS-CDG (Van
Karnebeek et al 2016), PGM3-CDG (Stray-Pedersen
et al 2014), and also in a tissue-specific and GA homeo-
stasis defect of VPS13B-CDG/Cohen syndrome
(Duplomb et al 2014).
Transferr in glycopeptide analysis , which was
established by Wada et al in 2004 is important to reveal
the structural information on both glycans and proteins.
For example, the hybrid type glycan which is diagnostic
for GA mannosidase defects of MAN1B1-CDG can only
be found at Asn-432 but not on Asn-630 (Wada 2016).
For O-glycan analysis, Wada et al developed plasma Apo
C-III MALDI MS (Wada et al 2012).
For plasma glycomics, MALDI MS was used to analyze
permethylated total plasma N-glycans (Guillard et al
2009), or combined plasma N-glycan and O-glycans MS
(Xia et al 2013). MALDI MS was also suitable to analyze
N-glycans released from fibroblast homogenates of
SLC35A3 and healthy controls (Edvardson et al 2013),
which is a useful alternative when transferrin glycosylation
turned out to be normal. The patient cell homogenate
showed a shift toward decreased branching of glycans
compared to control, likely due to the lack of UDP-
GlcNAc, which is a critical factor in the production of
β1,6-branched (tetra-antennary) structures (Sasai et al
2002).
Both total plasma and intact transferrin glycoprofiling
have their own advantages in the diagnosis of CDG.
Recently, intact transferrin MS has successfully identified
a series of novel CDG, such as PGM1-CDG (Tegtmeyer
et al 2014) and MAN1B1-CDG (van Scherpenzeel et al
2014). A unique combination of CDG-I (lack of complete
glycans) and CDG-II (truncated glycans especially lack-
ing Gal residue) in PGM1-CDG is easily seen by intact
transferrin glycoprofiling. Moreover, it is also used to
follow-up the biochemical improvement of several pa-
tients that underwent an oral D-galactose supplementation
(Voermans et al 2017, Wong et al 2017). It has become
the primary diagnostic test for CDG, also including fast
identif ication of B4GALT1-CDG, MGAT2-CDG,
SLC35A1-CDG, and SLC35A2-CDG (van Scherpenzeel
et al 2015).
However, there are several CDG types which cannot be
discriminated by intact transferrin glycoprofiling which re-
quired total (released) plasma N-glycans for structural in-
sights into the complete mixture of plasma glycoproteins.
For example, for diagnosis of SLC35C1-CDG (GDP-fucose
transporter defect), global N-glycan mapping is more suit-
able, because of its higher degree of fucosylation than intact
transferrin (Guillard et al 2011). It is also able to detect theN-
tetrasaccharide for ALG1-CDG diagnosis and highly abun-
dant abnormal high mannose species of 3 Man- and 4 Man-
glycans in PMM2-CDG and MPI-CDG (Zhang et al 2016),
and to show abnormal profiles for tissue-specific glycosyla-
tion defects for VPS13B-CDG, also called Cohen syndrome
(Duplomb et al 2014). In the case of MOGS-CDG which
showed a normal transferrin profile, accumulation of several
highmannose species from total IgGN-glycans were detect-
ed by plasma glycomics (Sadat et al 2014). In summary,
Table 1 provides a detailed overview of the glycoprofiling
data of total plasma N-glycans and intact transferrin for di-
agnosis of different CDG subtypes.
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Overview of the current CDG diagnostic
workflow
As one of the most abundant glycoproteins in human plasma,
transferrin has been used traditionally as a biomarker for N-
glycosylation defects. Plasma transferrin isoelectric focusing
(IEF) is recognized as the classical laboratory method (Jaeken
et al 1984) and widely used as a routine screening test for
CDG. Human transferrin has two glycosylation sites on
Asn-432 and Asn-630, carrying both a bi-antennary glycan
Table 1 Overview of plasma glycosylation features from total (released) N-glycans and intact transferrin MS profiling for CDG diagnosis
Gene 
defects
Released plasma N-glycans MS; total or protein specific Intact plasma transferrin MS 
MS Glycoprofiling MS 
techniques
Reference MS Glycoprofiling MS 
techniques
Reference
CDG-I (LLO assembly defects): GDP-Man synthesis defects
PMM2
(PMM2-
CDG)
&
MPI
(MPI-CDG)
Increase of total plasma 3 mannose glycans (Man3-
GlcNAc2), 4 mannose glycans (Man4-GlcNAc2) and 
sialylated tetrasaccharide glycans (Sia1-Gal1-GlcNAc2). 
, and 
Low ratio of total plasma could discriminate 
this group (PMM2-CDG and MPI-CDG) from ALG1-
CDG.
Maldi TOF 
MS
Zhang et al 
2016
Increase of typical CDG-I glycoforms; 
lack of both and one complete biantennary 
glycans (Sia2-Gal2-Man3-GlcNAc4), 
respectively.
and 
ESI-LC 
QMS 
&
ESI-LC 
MS, QTOF 
MS 
Lacey et al 
2001
&
Van 
Scherpenzeel 
et al 2015
CDG-I (LLO assembly defects): mannosylation defects 
ALG1 
(ALG1-CDG)
Increase of total plasma sialylated tetrasaccharide glycans 
(Sia1-Gal1-GlcNAc2), 3 mannose glycans (Man3-GlcNAc2) 
and 4 mannose glycans (Man4-GlcNAc2).
, and
High ratio of total plasma could discriminate 
ALG1-CDG from PMM2-CDG and MPI-CDG.
Maldi TOF 
MS
Zhang et al 
2016
Increase of two sialylated tetrasaccharide 
glycoforms; (Sia1-Gal1- GlcNAc2) and 
(Sia3-Gal3-Man3-GlcNAc6).
and 
ESI-LC 
MS, QTOF 
MS 
Bengtson et 
al 2016
CDG-II (glycan processing defects): ER glucosidase defects
MOGS
(MOGS-
CDG)
Increase of IgG glycans of 14-saccharides (Gluc3-Man9-
GlcNAc2), 13-saccharides (Gluc3-Man8- GlcNAc2) and 12-
saccharides (Gluc3-Man7- GlcNAc2).
, ,
Maldi TOF 
MS
Sadad et al 
2014
Normal transferrin profiles. Lefeber et al 
2011
CDG-II (glycan processing defects): glycosyltransferase defects
MGAT2 Most abundant of total plasma complex truncated Maldi TOF Guillard et Most abundant of complex truncated ESI-LC Van 
/
/
Gene 
defects
Released plasma N-glycans MS; total or protein specific Intact plasma transferrin MS 
MS Glycoprofiling MS 
techniques
Reference MS Glycoprofiling MS 
techniques
Reference
(MGAT2-
CDG)
biantennary glycan lacking one GlcNAc, one Gal and one 
Sia (Sia1-Gal1- Man3-GlcNAc3) with the corresponding 
fucosylated ones (Sia1-Gal1- Man3-GlcNAc3-Fuc1).
and
MS al 2011 biantennary glycoform lacking one 
GlcNAc, one Gal and one Sia (Sia2-Gal2-
Man6-GlcNAc6).
MS, QTOF 
MS 
Scherpenzeel 
et al 2015
B4GALT1
(B4GALT1-
CDG)
Most abundant of total plasma complex truncated 
biantennary glycan lacking all galactoses (Man3-GlcNAc4) 
with the corresponding fucosylated ones (Man3-GlcNAc4-
Fuc1).
and
Maldi TOF 
MS
Guillard et 
al 2011
Most abundant of complex truncated 
biantennary glycoform lacking all 
galactoses (Man6-GlcNAc8).
ESI-LC 
MS, QTOF 
MS 
Van 
Scherpenzeel 
et al 2015
CDG-II (glycan processing defects): Golgi mannosidase defects
MAN1B1 
(MAN1B1-
CDG)
Increase of several total plasma hybrid glycans with the 
corresponding fucosylated ones; (Sia1-Gal1- Man4-
GlcNAc3), (Sia1-Gal1- Man4-GlcNAc3-Fuc1), (Sia1-Gal1-
Man5-GlcNAc3), (Sia1-Gal1- Man5-GlcNAc3-Fuc1), and 6
mannose glycans; (Man6-GlcNAc2).
, , , and
Maldi TOF 
MS
Rymen et 
al 2013
Increase of two hybrid glycoforms; (Sia3-
Gal3-Man8-GlcNAc7) and (Sia3-Gal3-
Man7-GlcNAc7).
and 
ESI-LC 
MS, QTOF 
MS 
Van 
Scherpenzeel 
et al 2014
&
Van 
Scherpenzeel 
et al 2015
CDG-II (glycan processing defects): nucleotide sugar transporter defects
SLC35C1 
(SLC35C1-
CDG)
Decrease of major total plasma fucosylated glycans; e.g. 
(Sia2-Gal2- Man3-GlcNAc4-Fuc1), (Sia1-Gal2- Man3-
GlcNAc4-Fuc1), (Gal2- Man3-GlcNAc4-Fuc1) and (Gal1-
Man3-GlcNAc4-Fuc1).
, , and
Maldi TOF 
MS
Guillard et 
al 2011
Normal transferrin profiles. Lefeber et al 
2011
SLC35A1 
(SLC35A1-
CDG)
Increase of total plasma complex truncated biantennary 
glycan lacking one Sia (Sia1-Gal2- Man3-GlcNAc4) with 
the corresponding fucosylated ones (Sia1-Gal2- Man3-
Maldi TOF 
MS
Mohamed 
et al 2013
Increase of complex truncated biantennary 
glycoform lacking one and two Sia, 
respectively; (Sia3-Gal4-Man6-GlcNAc8) 
ESI-LC 
MS, QTOF 
MS 
Van 
Scherpenzeel 
et al 2015
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with two terminal, negatively charged sialic acid residues. In
normal conditions, most transferrin molecules consist of a
total of four sialic acid residues which are displayed as a single
major band of tetrasialo-transferrin in the IEF pattern (Fig. 2a).
The CDG-I IEF pattern shows an increased band of disialo-
transferrin and asialo-transferrin, owing to the occurrence of
Table 1 (continued)
Gene 
defects
Released plasma N-glycans MS; total or protein specific Intact plasma transferrin MS 
MS Glycoprofiling MS 
techniques
Reference MS Glycoprofiling MS 
techniques
Reference
GlcNAc4-Fuc1).
and
and (Sia2-Gal4-Man6-GlcNAc8). 
and 
SLC35A2 
(SLC35A2-
CDG)
Increase of total plasma complex truncated biantennary 
glycan lacking Gal and Sia; (Man3-GlcNAc4) and (Sia1-
Gal1- Man3-GlcNAc4).
and
Maldi TOF 
MS
Xia et al 
2013
Consistent Increase of complex truncated
glycoform lacking Gal and Sia; (Sia3-
Gal3-Man6-GlcNAc8), (Sia2-Gal2-Man6-
GlcNAc8), (Sia1-Gal1-Man6-GlcNAc8) and 
(Man6-GlcNAc8).
, , and 
ESI-LC 
MS, QTOF 
MS 
Van 
Scherpenzeel 
et al 2015
&
Dorre et al 
2015
CDG-II (glycan processing defects): Golgi homeostasis defects
ATP6V0A2
(ATP6V0A2-
CDG)
Increase of several total plasma complex truncated 
biantennary glycan lacking Gal and Sia, and fucosylated 
ones; (Man3-GlcNAc4-Fuc1), (Gal1- Man3-GlcNAc4-Fuc1), 
(Sia1-Gal1- Man3-GlcNAc4), (Sia1-Gal2- Man3-GlcNAc4) 
and (Sia1-Gal2- Man3-GlcNAc4-Fuc1), and 5 mannose 
glycans (Man5-GlcNAc2).
, , , , and
Maldi TOF 
MS
Guillard et 
al 2011
Increase of complex truncated glycoform 
lacking one Sia; (Sia3-Gal4-Man6-
GlcNAc8) followed by minor Increase of 
several complex truncated glycoform 
lacking Gal and Sia; (Sia3-Gal3-Man6-
GlcNAc8), (Sia2-Gal4-Man6-GlcNAc8), 
(Sia2-Gal3-Man6-GlcNAc8) and (Sia2-
Gal2-Man6-GlcNAc8)
, , , 
and 
ESI-LC 
MS, QTOF 
MS 
Van 
Scherpenzeel 
et al 2015
ATP6AP1
(ATP6AP1-
CDG)
Increase of several total plasma complex truncated 
biantennary glycan lacking Gal and Sia, and fucosylated 
ones ; (Man3-GlcNAc4-Fuc1), (Man3-GlcNAc5), (Man3-
GlcNAc5-Fuc1), (Gal1- Man3-GlcNAc4-Fuc1), (Gal2- Man3-
Maldi TOF 
MS
Jansen et al 
2016a
Increase of complex truncated glycoform 
lacking one Sia; (Sia3-Gal4-Man6-
GlcNAc8) followed by minor Increase of 
several complex truncated glycoform 
ESI-LC 
MS, QTOF 
MS 
Van 
Scherpenzeel 
et al 2015
& 
Gene 
defects
Released plasma N-glycans MS; total or protein specific Intact plasma transferrin MS 
MS Glycoprofiling MS 
techniques
Reference MS Glycoprofiling MS 
techniques
Reference
GlcNAc4-Fuc1), (Sia1-Gal2- Man3-GlcNAc4) and (Sia1-
Gal2- Man3-GlcNAc4-Fuc1), and 5 mannose glycans (Man5-
GlcNAc2).
, , , , , , and
lacking Gal and Sia; (Sia2-Gal4-Man6-
GlcNAc8) and (Sia2-Gal3-Man6-GlcNAc8). 
, and 
Jansen et al 
2016a
ATP6V1A
(ATP6V1A-
CDG)
Not reported NA NA Increase of complex truncated glycoform 
lacking one Sia; (Sia3-Gal4-Man6-
GlcNAc8) followed by minor Increase of 
complex truncated glycoform lacking two 
Sia (Sia2-Gal4-Man6-GlcNAc8). 
and 
ESI-LC 
MS, QTOF 
MS 
Van Damme 
et al 2016 
ATP6V1E1
(ATP6V1E1-
CDG)
Not reported NA NA Increase of complex truncated glycoform 
lacking one Sia; (Sia3-Gal4-Man6-
GlcNAc8) followed by minor Increase of
several complex truncated glycoform 
lacking Gal and Sia; (Sia3-Gal3-Man6-
GlcNAc8), (Sia2-Gal4-Man6-GlcNAc8), 
(Sia2-Gal3-Man6-GlcNAc8) and (Sia2-
Gal2-Man6-GlcNAc8)
, , , 
, and 
ESI-LC 
MS, QTOF 
MS 
Van Damme 
et al 2016 
TMEM165
(TMEM165-
CDG)
Increase of several total plasma complex truncated 
biantennary glycan lacking Gal and Sia, and fucosylated 
ones; (Man3-GlcNAc3), (Man3-GlcNAc4), (Man3-GlcNAc4-
Fuc1), (Gal1- Man3-GlcNAc4), (Gal1- Man3-GlcNAc4-
Fuc1), (Sia1-Gal1- Man3-GlcNAc3), (Sia1-Gal1- Man3-
Maldi TOF 
MS
Foulquier 
et al 2012
&
Xia et al 
2013
Increase of several complex truncated 
glycoform lacking Gal and Sia; (Sia3-
Gal4-Man6-GlcNAc8), (Sia3-Gal3-Man6-
GlcNAc8), (Sia2-Gal3-Man6-GlcNAc8), 
(Sia2-Gal2-Man6-GlcNAc8) and (Sia1-
ESI-LC 
MS, QTOF 
MS 
Van 
Scherpenzeel 
et al 2015
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transferrin isoforms with two sialic acids and no sialic acid,
respectively (Fig. 2b). CDG-II IEF patterns show high vari-
ability as depicted for MGAT2-CDG (Fig. 2c), MAN1B1-
CDG (Fig. 2d), and B4GALT1-CDG (Fig. 2e), with increased
trisialo-transferrin or increased asialo- and monosialo-trans-
ferrin, respectively. Untreated hereditary fructosemia and
Table 1 (continued)
Gene 
defects
Released plasma N-glycans MS; total or protein specific Intact plasma transferrin MS 
MS Glycoprofiling MS 
techniques
Reference MS Glycoprofiling MS 
techniques
Reference
GlcNAc3-Fuc1), (Sia1-Gal1- Man3-GlcNAc4), (Sia1-Gal2-
Man3-GlcNAc4) and (Sia1-Gal2- Man3-GlcNAc4-Fuc1), and
5 mannose glycans (Man5-GlcNAc2).
, , , , , , , , , and
Gal1-Man6-GlcNAc8).
, , , 
and  
TMEM199
(TMEM199-
CDG)
Not reported NA NA Increase of several complex truncated 
glycoform lacking Gal and Sia; (Sia3-
Gal4-Man6-GlcNAc8), (Sia3-Gal3-Man6-
GlcNAc8), (Sia2-Gal3-Man6-GlcNAc8), 
(Sia2-Gal2-Man6-GlcNAc8) and (Sia1-
Gal1-Man6-GlcNAc8).
, , , 
and  
ESI-LC 
MS, QTOF 
MS 
Jansen et al 
2016b
CCDC115
(CCDC115-
CDG)
Increase of several total plasma complex truncated 
biantennary glycan lacking Gal and Sia, and fucosylated 
ones; (Gal1- Man3-GlcNAc4-Fuc1), (Sia1-Gal1- Man3-
GlcNAc4), (Sia1-Gal2- Man3-GlcNAc4) and (Sia1-Gal2-
Man3-GlcNAc4-Fuc1).
, , and
Maldi TOF 
MS
Jansen et al 
2016c
Increase of several complex truncated 
glycoform lacking Gal and Sia; (Sia3-
Gal4-Man6-GlcNAc8), (Sia3-Gal3-Man6-
GlcNAc8), (Sia2-Gal3-Man6-GlcNAc8), 
(Sia2-Gal2-Man6-GlcNAc8) and (Sia1-
Gal1-Man6-GlcNAc8).
, , , 
and  
LC/MS, 
QTOF
Jansen et al 
2016c
SLC39A8 Not reported NA NA Increase of several complex truncated ESI-LC Park et al 
Gene 
defects
Released plasma N-glycans MS; total or protein specific Intact plasma transferrin MS 
MS Glycoprofiling MS 
techniques
Reference MS Glycoprofiling MS 
techniques
Reference
(SLC39A8-
CDG)
glycoform lacking Gal and Sia; (Sia3-
Gal4-Man6-GlcNAc8), (Sia3-Gal3-Man6-
GlcNAc8), (Sia2-Gal3-Man6-GlcNAc8), 
(Sia2-Gal2-Man6-GlcNAc8), (Sia1-Gal2-
Man6-GlcNAc8) and (Sia1-Gal1-Man6-
GlcNAc8).
, , , ,    
and  
TOF MS, 2015 
VPS13B
(VPS13B-
CDG / Cohen 
syndrome)
Increase of several total plasma complex truncated 
biantennary glycan lacking Gal and Sia, and fucosylated 
ones; (Man3-GlcNAc4-Fuc1), (Gal1- Man3-GlcNAc4), 
(Gal1- Man3-GlcNAc4-Fuc1), (Sia1-Gal2- Man3-GlcNAc4) 
and (Sia1-Gal2- Man3-GlcNAc4-Fuc1).
, , , and 
Maldi TOF 
MS
Duplomb et 
al 2014
Normal transferrin profiles. IEF Duplomb et 
al 2014
CDG-II (glycan processing defects): Golgi trafficking defects
COG1
(COG1-CDG)
Increase of several total plasma complex truncated 
biantennary glycan lacking Gal and Sia, and fucosylated 
ones; (Man3-GlcNAc4-Fuc1), (Sia1-Gal1- Man3-GlcNAc4), 
(Sia1-Gal2- Man3-GlcNAc4) and (Sia1-Gal2- Man3-
GlcNAc4-Fuc1), and 5 mannose glycans (Man5-GlcNAc2).
, ,  , and
Maldi TOF 
MS
Foulquier 
et al 2006
&
Reynders et 
al 2009
Increase of complex truncated glycoform 
lacking one sialic acid; (Sia3-Gal4-Man6-
GlcNAc8) followed by minor Increase of 
complex truncated glycoform lacking Gal
and Sia; (Sia2-Gal4-Man6-GlcNAc8) and 
(Sia2-Gal3-Man6-GlcNAc8).
, and 
ESI-LC 
MS, QTOF 
MS 
Van 
Scherpenzeel 
et al 2015
COG4
(COG4-CDG)
Increase of several total plasma complex truncated 
biantennary glycan lacking Gal and Sia; (Gal1- Man3-
GlcNAc4), (Sia1-Gal1- Man3-GlcNAc4) and (Sia1-Gal2-
Maldi TOF 
MS
Reynders et 
al 2009
&
Not reported
506 J Inherit Metab Dis (2018) 41:499–513
galactosemia, alcohol abuse, hepatopathy, and bacterial
sialidases are known as secondary causes of abnormal trans-
ferrin glycosylation.
The diagnostics follow-up for CDG-I profiles started with
an enzyme assay in fibroblasts or leukocytes for diagnosis of
PMM2-CDG and PMI-CDG. If negative, the next step was to
perform lipid-linked oligosaccharides (LLO) in fibroblasts
(Gao and Lehrman 2002), or recently this has been replaced
by WES using a filter for CDG-I genes and targeted sequenc-
ing of a CDG-I panel (Timal et al 2012). The recent discovery
of a novel sialylated N-tetrasaccharide for ALG1-CDG and
abnormal small high mannose glycan structures in PMM2-
CDG and MPI-CDG has proved plasma N-glycan analysis
to also be relevant for CDG-I diagnosis. Hence, plasma
Table 1 (continued)
Gene 
defects
Released plasma N-glycans MS; total or protein specific Intact plasma transferrin MS 
MS Glycoprofiling MS 
techniques
Reference MS Glycoprofiling MS 
techniques
Reference
Man3-GlcNAc4), and 5 mannose glycans (Man5-GlcNAc2).
, , and
Xia et al 
2013
COG5
(COG5-CDG)
Increase of several total plasma complex truncated 
biantennary glycan lacking Gal and Sia, and fucosylated 
ones; (Man3-GlcNAc4-Fuc1), (Gal1- Man3-GlcNAc4-Fuc1), 
(Gal2- Man3-GlcNAc4-Fuc1), (Sia1-Gal2- Man3-GlcNAc4) 
and (Sia1-Gal2- Man3-GlcNAc4-Fuc1). 
, , , and
Maldi TOF 
MS
Palmigiano 
et al 2017
Increase of complex truncated biantennary 
glycoform lacking one Sia (Sia3-Gal4-
Man6-GlcNAc8).
ESI-LC MS Paesold-
Burda et al 
2009
COG6
(COG6-CDG)
Increase of transferrin glycans of complex truncated 
biantennary glycan lacking Gal and Sia; (Sia1-Gal1- Man3-
GlcNAc4) and (Sia1-Gal2- Man3-GlcNAc4).
and
Maldi TOF 
MS
Huybrechts 
et al 2012
Not reported NA NA
COG7
(COG7-CDG)
Increase of several total plasma complex truncated 
biantennary glycan lacking Gal and Sia, and fucosylated 
ones; (Man3-GlcNAc4-Fuc1), (Gal1- Man3-GlcNAc4), 
(Gal1- Man3-GlcNAc4-Fuc1), (Sia1-Gal1- Man3-GlcNAc4), 
(Sia1-Gal2- Man3-GlcNAc4) and (Sia1-Gal2- Man3-
GlcNAc4-Fuc1), and 5 mannose glycans (Man5-GlcNAc2).
, , , , , and
Maldi TOF 
MS
Reynders et 
al 2009 
&
Ng et al 
2011
&
Guillard et 
al 2011
&
Xia et al 
2013
Not reported NA NA
COG8
(COG8-CDG)
Increase of total plasma complex truncated biantennary 
glycan lacking Gal and Sia; (Sia1-Gal1- Man3-GlcNAc4) 
and (Sia1-Gal2- Man3-GlcNAc4).
Maldi TOF 
MS
Foulquier 
et al 2007
&
Kranz et al 
Increase of complex truncated biantennary 
glycoform lacking one and two Sia, 
respectively; (Sia3-Gal4-Man6-GlcNAc8) 
and (Sia2-Gal4-Man6-GlcNAc8).
ESI-LC MS Kranz et al 
2007
Gene 
defects
Released plasma N-glycans MS; total or protein specific Intact plasma transferrin MS 
MS Glycoprofiling MS 
techniques
Reference MS Glycoprofiling MS 
techniques
Reference
and 
2007
&
Reynders et 
al 2009
and 
Mixed CDG-I &-II (Mixed ER & Golgi defects)
PGM1
(PGM1-CDG)
Increase of several total plasma complex truncated 
biantennary glycan lacking Gal and Sia; (Man3-GlcNAc4), 
(Sia1-Gal1- Man3-GlcNAc4) and (Sia1-Gal2- Man3-
GlcNAc4).
,  and  
Maldi TOF 
MS
Xia et al 
2013
Increase of typical CDG-I glycoforms; 
lack of both and one complete biantennary 
glycans (Sia2-Gal2-Man3-GlcNAc4), 
respectively.
and 
Increase of several complex truncated 
glycoform lacking Gal and Sia; e.g. 
(Man3-GlcNAc4), (Sia1-Gal1- Man3-
GlcNAc4), (Sia1-Gal1-Man6-GlcNAc8), 
(Sia2-Gal2-Man6-GlcNAc8), (Sia3-Gal3-
Man6-GlcNAc8) and (Sia3-Gal4-Man6-
GlcNAc8).
, , , 
, and 
LC/MS, 
QTOF
Tegtmeyer et 
al 2014 
&
Van 
Scherpenzeel 
et al 2015
Glycan features identified by either one of these glycomics methods were listed here. It should be noted that patient numbers are in general too small to establish
statistically correct ranges of relative abundance for the different genetic defects. However, the presence of specific glycan features is often already highly
characteristic for specific genetic disorders
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glycomics is highly useful especially for ALG1-CDG, since it
is challenging to identify the defect by genetics due to 14
pseudo genes that can complicate the analysis (Zhang et al
2016). Another upcoming diagnostic choice is applying
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WES directly and Sanger sequencing to confirm the gene
defect, but up till now it takes more time to result and is more
expensive than conventional CDG screening (Van
Scherpenzeel et al 2016).
The diagnostic follow-up approach for CDG-II profiles is
an IEF assay of Apo C-III to profile the mucin type O-glycans
(Wopereis et al 2003), to distinguish between an exclusive N-
glycosylation defect and a combined disorder of N- and O-
glycosylation (Wopereis et al 2007). Apo C-III has only a
single O-glycan on Thr-74 which is terminally modified by
up to two sialic acids to generate three main IEF isoforms:
Apo C-III0 (no sialic acid), Apo C-III1 (one sialic acid), and
Apo C-III2 (two sialic acids). Decreased sialylation on Apo C-
III profiles has been reported in conserved oligomeric Golgi
(COG) defects (Spaapen et al 2005; Foulquier et al 2006;
Foulquier et al 2007; Kranz et al 2007; Morava et al 2007;
Wopereis et al 2007; Zeevaert et al 2008; Ng et al 2011;
Palmigiano et al 2017) and autosomal recessive cutis laxa
type-2 (ARCL2) due to ATP6V0A2 dysfunctions (Morava
et al 2005; Kornak et al 2008). The limitation of Apo C-III
IEF is that it is not able to differentiate between the three
possible Apo C-III0 isoforms; the Breal unglycosylated Apo
C-III^ and Apo C-III with two non-sialylated monosaccha-
rides namely Gal and GalNAc. They can easily be separated
by Apo C-III MALDI MS (Wada 2016).
So for more structural insight in glycans especially in
CDG-II patients, MS is always the method of choice. This
rapid profiling of abnormal glycans can be linked to potential
gene defects based on the knowledge of glycosylation path-
ways. For example (Fig. 2): Detection of N-tetrasaccharide
glycans in ALG1-CDG might be explained by the modifica-
tion (galactosylation and sialylation) of the chitobiose glycan
core, which accumulates due to cytosolic mannosyltransferase
defects; Accumulation of truncated N-glycans lacking
GlcNAc in MGAT2-CDG is likely due to the N-
acetylglucosaminyltransferase defects in GA; Accumulation
of truncated N-glycans lacking Gal could be due to
B4GALT1 gene defect, encoding for galactosyltransferase in
GA. Accumulation of hybrid N-glycans in MAN1B1-CDG is
due to the ER mannosyltransferase defects. The structural in-
formation is important to narrow down the number of candi-
date genes, thereby greatly minimizing the time to diagnosis.
The complete diagnostic workflow as described above is
depicted in Fig. 3.
Outlook
Based on the identification of several new genetic defects
over the past four years by a combination of high-resolution
intact transferrin analysis with WES, it might be concluded
that clinical glycomics and NGS technology work in syn-
ergy by reducing the number of candidate genes and turn-
around time to identify a CDG subtype. This approach cre-
ates opportunities to identify new genetic defects, but be-
yond this observation, glycomics has the benefit that the
data do not only reflect the genes, but also environmental
influences, which create possibilities for therapy monitor-
ing and intervention. The first example was PGM1-CDG
(Voermans et al 2017), but nowadays, several new genetic
defects appear to be involved in sugar metabolism.
Surprisingly, not all these genetic defects show abnormal
transferrin glycosylation. Examples are NANS, GNE,
PGM3, and Cohen syndrome. NANS and GNE are genetic
defects in the sialic acid biosynthesis pathway, and Cohen
syndrome patients have a mutation in VPS13B, a protein
important for proper GA function. It is known that there
are tissue-specific glycosylation processes, for example
gamma-glutamyl transpeptidase synthetized by the liver
or the kidney (West et al 2010), and that there will be other
proteins than transferrin which do show abnormal glycosyl-
ation, e.g., muscle proteins for GNE patients.
Native glycopeptide profiling would be an attractive meth-
od to obtain insight into protein-specific glycosylation. For
some isolated proteins like human transferrin, human alpha-
1-acid glycoprotein, influenza Avirus hemagglutinin, and hu-
man IgG, this has been performed (Khatri et al 2014). If this
could work for highly complex protein mixtures like serum or
Fig. 2 Intact transferrin IEF andMS profiles, and total plasma N-glycans
MS profiles in healthy control, ALG1-CDG (cdg-Ik), MGAT2-CDG
(cdg-IIa), MAN1B1-CDG, and B4GALT1-CDG (cdg-IIb).
Deconvoluted QTOF mass spectrum of intact transferrin showed a high
intensity of the peak indicating: (a) two bi-antennary fully sialylated
(complete) glycoforms (79,557 Da) corresponding with the major
presence of tetrasialo-transferrin bands on IEF patterns in healthy
control; (b) lack of both (75,146 Da) and one (77,351 Da) complete
glycoforms (CDG-I signatures) corresponding with the major increase
of asialo- and disialo-transferrin bands on IEF patterns, as well as two
minor peaks indicating the N-tetrasaccharide (76,007 & 78,212 Da) in
ALG1-CDG; (c) two truncated glycoforms lacking N-acetylglucosamine
(78,243 & 78,900 Da) corresponding with the major increase of trisialo-
and disialo-transferrin bands on IEF patterns in MGAT2-CDG; (d) two
hybrid glycoforms (79,059 & 79,221 Da) corresponding with the major
increase of trisialo-transferrin bands on IEF patterns in MAN1B1-CDG;
(e) five truncated glycoform lacking galactose (77,541, 77,743, 77,947,
78,196, & 78,399 Da), which are mostly non-sialylated species,
corresponding with the major increase of asialo- and monosialo-
transferrin on IEF patterns (mimicking CDG-I profiles) in B4GALT1-
CDG. Extracted compound chromatrograms (ECCs) of isomeric native
total plasma N-glycans profiling showed the most abundant compound
peaks indicating: (f) di- and mono-sialylated bi-antennary N-glycans (5.6
& 7.2 min, respectively) in healthy control; (g) N-tetrasaccharide (6.8 &
8.2 min) in ALG1-CDG; (h) mono-sialylated N-glycans lacking N-
acetylglucosamine (6.6 & 7.4 min) and its fucosylated species (7.6 &
8.3 min) in MGAT2-CDG; (i) hybrid N-glycans (6.1 & 6.7 min) and its
fucosylated species (7.0 & 7.6 min) in MAN1B1-CDG; (j) two non-
sialylated N-glycans lacking galactose, tri-antenna (2.9 & 3.4 min), and
bi-antenna (4.2 & 4.9 min), and its fucosylated species; tri-antennary (4.1
& 4.4 min) and bi-antennary glycans (5.3 & 5.9 min) in B4GALT1-CDG
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plasma (Zielinska et al 2010), an enormous amount of data
would show up and provide us with new mechanistic insights
into tissue-specific glycosylation and likely yield several gly-
coprotein biomarkers for CDG and also common disorders
(Yang et al 2017). Knowledge about the human
glycoproteome is still very limited, but this new system-
wide mapping technology will allow the study of fundamental
questions in glycobiology, such as dynamics, macro- and mi-
croheterogeneity, tissue-specific glycosylation, and the func-
tion of certain glycans in specific biological contexts
(Thaysen-Andersen and Packer 2014). In this context, genetic
deficiencies beyond the classical CDG, which are in O-glyco-
sylation, e.g., in O-GalNAc, O-mannose, and O-fucose glyco-
sylation or in glycolipid or glycosaminoglycan biosynthesis
(comprehensive review in Hennet 2012), have to be men-
tioned. There is no general diagnostic test available for these
rare genetic disorders because of the structural heterogeneity
of O-glycans and their tissue-specific expression. Because of
the advancement in genetics and bioinformatics, we foresee
glycomics becoming interlinked with metabolomics and pro-
teomics, thereby opening research avenues to unravel protein
glycosylation in a tissue- or cell-specific manner, to under-
stand the biochemical mechanisms of glycosylation, and to
ultimately develop or improve new (sugar based) therapies
for this group of so far mainly untreatable disorders.
Another advance in technology is intact protein profiling.
Both in the chromatographic part as well as the data analysis
there are recent developments which enable the analysis of
protein mixtures to have multiple biomarkers in one assay. A
large number of biomarkers used in clinical laboratories are
glycopeptides of which variations in glycosylation are not
taken into account, and only protein expression levels are
measured. Examples are alpha-1-antitrypsin for chronic ob-
structive pulmonary disease (COPD), haptoglobin for gastric
cancer, and human chorionic gonadotrophin for ovarian and
testicular tumors (Van Scherpenzeel et al 2016). For two intact
plasma glycoproteins, namely alpha-fetoprotein and transfer-
rin, it is already known that it is essential to include glycosyl-
ation analysis for specificity and sensitivity of the marker.
There is an enormous potential to improve first line diagnosis
when the level of glycosylation is taken into account on top of
the current protein expression levels. With the upcoming use
of targeted mass spectrometry in clinical laboratories, the gly-
can part of the biomarker might easily be included to improve
sensitivity and specificity of the marker without additional
time-to-result.
With the example of effective D-galactose supplementation
on the improvement of glycosylation in PGM1-CDG, which
was derived from the intact transferrin glycosylation profile
(Tegtmeyer et al 2014), there is emerging interest in the appli-
cation of sugars as supplemental therapies for metabolic dis-
orders or as supportive therapy to improve the mechanism of
action of known therapies, such as chemotherapy, for which 2-
deoxyhexose was used to enhance the therapeutic effect by
inhibiting glycolysis and even induce an effective antitumor
immune response (Beneteau et al 2012). The way to obtain
insight into these mechanisms will be one new glycomics
area, in which the building blocks of glycosylation, compris-
ing sugar-phosphates and nucleotide sugars, are analyzed. By
studying the flux through sugar metabolism, dynamic insights
will be obtained, which could lead to the development of new
therapies and improve current ones. Bioinformatics will
Fig. 3 Clinical diagnostic
flowchart for CDG. The
combination of mass
spectrometry with clinical exome
sequencing and clinical
phenotyping allows facile
identification of the majority of
known CDG-I and CDG-II
subtypes in a diagnostic setting.
The gene defects mentioned here
are examples of characteristic
diagnostic glycomics profiles in
our laboratory. Please refer to
Jaeken and Peanne (2017) and
Peanne et al (2017) for clinical
symptoms in CDG
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become increasingly important to extract the relevant infor-
mation out of these big data sets, to visualize, and potentially
integrate with other omics layers of information, for better
understanding of the complex field of glycobiology.
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